|
RUFY2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.53279611225798E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.11319994836145E-09 |
| Normal-vs-Stage2 |
4.1405999962052E-08 |
| Normal-vs-Stage3 |
2.37330000096847E-09 |
| Normal-vs-Stage4 |
4.22879999906201E-08 |
| Stage1-vs-Stage2 |
1.019370E-01 |
| Stage1-vs-Stage3 |
2.427800E-01 |
| Stage1-vs-Stage4 |
2.452000E-01 |
| Stage2-vs-Stage3 |
4.810000E-01 |
| Stage2-vs-Stage4 |
6.637400E-01 |
| Stage3-vs-Stage4 |
8.072800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.85670367969237E-11 |
| Normal-vs-AfricanAmerican |
3.409900E-02 |
| Normal-vs-Asian |
2.2838000000025E-06 |
| Caucasian-vs-AfricanAmerican |
3.802400E-02 |
| Caucasian-vs-Asian |
7.469800E-01 |
| AfricanAmerican-vs-Asian |
1.263000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.74519978865828E-10 |
| Normal-vs-Female |
1.62630020561494E-10 |
| Male-vs-Female |
6.676400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.85290000009886E-08 |
| Normal-vs-Age(41-60Yrs) |
1.21470000724599E-09 |
| Normal-vs-Age(61-80Yrs) |
6.71170008459399E-10 |
| Normal-vs-Age(81-100Yrs) |
2.039100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.226010E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.583500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.371200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.107200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.115800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.402200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.238000E-02 |
| Classical-VS-Follicular |
1.510490E-02 |
| Classical-VS-Other |
3.850800E-01 |
| Classical-VS-Normal |
1.05220000490291E-08 |
| Tall-VS-Follicular |
6.035200E-01 |
| Tall-VS-Other |
8.115600E-01 |
| Tall-VS-Normal |
1.90179999526308E-08 |
| Follicular-VS-Other |
9.716000E-01 |
| Follicular-VS-Normal |
5.82729997589126E-09 |
| Other-VS-Normal |
7.655500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.44949665790296E-11 |
| Normal-vs-N1 |
2.30900000000034E-05 |
| N0-vs-N1 |
2.997800E-01 |
|
|
